AVIR vs. INO, DAWN, MIRM, ABCL, ELVN, COLL, PRTA, ARQT, SAVA, and GYRE
Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Inovio Pharmaceuticals (INO), Day One Biopharmaceuticals (DAWN), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Prothena (PRTA), Arcutis Biotherapeutics (ARQT), Cassava Sciences (SAVA), and Gyre Therapeutics (GYRE). These companies are all part of the "medical" sector.
Inovio Pharmaceuticals (NASDAQ:INO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 2.5% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Inovio Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
Atea Pharmaceuticals has a net margin of 0.00% compared to Atea Pharmaceuticals' net margin of -16,238.91%. Inovio Pharmaceuticals' return on equity of -29.18% beat Atea Pharmaceuticals' return on equity.
Inovio Pharmaceuticals received 700 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 71.49% of users gave Inovio Pharmaceuticals an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
Inovio Pharmaceuticals has higher earnings, but lower revenue than Atea Pharmaceuticals.
Inovio Pharmaceuticals currently has a consensus price target of $70.67, suggesting a potential upside of 597.60%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Atea Pharmaceuticals.
In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for Inovio Pharmaceuticals and 2 mentions for Atea Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.94 beat Atea Pharmaceuticals' score of -0.13 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.
Summary
Inovio Pharmaceuticals beats Atea Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Atea Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atea Pharmaceuticals Competitors List
Related Companies and Tools
